# Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC

> **NCT06978829** · PHASE2 · RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 42 (estimated)

## Conditions studied

- LA HNSCC

## Interventions

- **DRUG:** TP + Cetuximab + Tislelizumab

## Key facts

- **NCT ID:** NCT06978829
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978829, "Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06978829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*